Hang on to your hats people - the anxiety problems that analysts were having over declining Procrit sales is being helped by our friends in Washington. For once we can say the govt. has helped us. By not approving to pay for Amgen's expensive medication, Medicare will boost Procrit sales.
Now, when the Cypher numbers come in bigger than expected, we will have a POP - and it won't be the sound of ML anlaysts pulling their heads out of their asses.
Here's to the Longs and all of you that bought in at $50 - cheers!
I agree that despite BS from Lemaitre at ML (must have some conflict to back BSX at the level he is), Cypher is continuing to take over stent market. My info is that yields in production are way up, with nearly 30,000 stents per week now entering the five week pipeline to enter into market. By Sept. labs will have very good inventory. If you do the math 30K/week at $2800/stent -> yields > $4 billion in annual sales by October. So much for ML BS. Postings on BSX board with regard to prolonged taxol retention and polymer erodability on Taxol product could lead to long and painful inquisition for BSX prior to approval. JNJ still clearly in the driver's seat, and car is taking off. Shorts should cover or face the music.